Interleukin 4 as a potential drug candidate for psoriasis

Expert Opinion on Drug Discovery

Volumn 3, Issue 3, 2008, Pages 357-368

  Weigert, Christina ^a   Röcken, Martin ^a   Ghoreschi, Kamran ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Biologics; Immune modulation; Interleukin 4; Psoriasis; TH2 immune response

Indexed keywords

ALEFACEPT; CD3 ANTIBODY; CD4 ANTIBODY; CYCLOSPORIN; EFALIZUMAB; INTERLEUKIN 12 ANTIBODY; INTERLEUKIN 23P19; INTERLEUKIN 4; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; METHOTREXATE; PLACEBO; RECOMBINANT INTERLEUKIN 10; RECOMBINANT INTERLEUKIN 11; RECOMBINANT INTERLEUKIN 4; TUMOR NECROSIS FACTOR;

ANEMIA; ANTIINFLAMMATORY ACTIVITY; ASTHMA; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG INHIBITION; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; DRUG WITHDRAWAL; FEVER; FLU LIKE SYNDROME; HEADACHE; HEAT SENSATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOPATHOGENESIS; LEUKOCYTE COUNT; LYMPHOCYTE ACTIVATION; MULTIPLE SCLEROSIS; NAUSEA; NONHUMAN; PRIORITY JOURNAL; PSORIASIS; PSORIASIS VULGARIS; PUVA; REVIEW; RHINITIS; SIDE EFFECT; SINGLE DRUG DOSE; SWELLING; THROMBOCYTOPENIA; WEIGHT GAIN;

EID: 41149114620     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460441.3.3.357     Document Type: Review

References (102)

1. Schon MP, Boehncke WH. Psoriasis. N Engl J Med 2005;352:1899-912
2. Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet 2007;370:263-71
3. Reich K, Westphal G, Schulz T, et al. Combined analysis of polymorphisms of the tumor necrosis factor-alpha and interleukin-10 promoter regions and polymorphic xenobiotic metabolizing enzymes in psoriasis. J Invest Dermatol 1999;113:214-20
4. Weisenseel P, Laumbacher B, Besgen P, et al. Streptococcal infection distinguishes different types of psoriasis. J Med Genet 2002;39:767-8
5. Baker BS, Laman JD, Powles A, et al. Peptidoglycan and peptidoglycan-specific Th1 cells in psoriatic skin lesions. J Pathol 2006;209:174-81
6. Fierlbeck G, Rassner G, Muller C. Psoriasis induced at the injection site of recombinant interferon gamma. Results of immunohistologic investigations. Arch Dermatol 1990;126:351-5
7. Menter A, Griffiths CE. Current and future management of psoriasis. Lancet 2007;370:272-84
8. Ghoreschi K, Rocken M. Immune deviation strategies in the therapy of psoriasis. Curr Drug Targets Inflamm Allergy 2004;3:193-8
9. Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature 1996;383:787-93
10. Laurence A, O'Shea JJ. T(H)-17 differentiation: of mice and men. Nat Immunol 2007;8:903-5
11. Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Ann Rev Immunol 1989;7:145-73
12. Le Gros G, Ben-Sasson SZ, Seder R, et al. Generation of interleukin 4 (IL-4)-producing cells in vivo and in vitro: IL-2 and IL-4 are required for in vitro generation of IL-4-producing cells. J Exp Med 1990;172:921-9
13. Singh R, Aggarwal A, Misra R. Th1/Th17 Cytokine Profiles in Patients with Reactive Arthritis/Undifferentiated Spondyloarthropathy. J Rheumatol 2007;34:2285-90
14. Lock C, Hermans G, Pedotti R, et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med 2002;8:500-8
15. Ghoreschi K, Thomas P, Breit S, et al. Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease. Nat Med 2003;9:40-6
16. Zheng Y, Danilenko DM, Valdez P, et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007;445:648-51
17. Ghoreschi K, Weigert C, Rocken M. Immunopathogenesis and role of T cells in psoriasis. Clin Dermatol 2007;25:574-80
18. Murray C, Mann DL, Gerber LN, et al. Histocompatibility alloantigens in psoriasis and psoriatic arthritis. Evidence for the influence of multiple genes in the major histocompatibility complex. J Clin Invest 1980;66:670-5
19. Kaudewitz P, Braun-Falco O, Kind P, et al. Distribution of T-cell subsets as defined by monoclonal antibodies in skin lesions of psoriasis vulgaris. Arch Dermatol Res 1984;276(1):33-5
20. Heydendael VM, Spuls PI, Opmeer BC, et al. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med 2003;349:658-65
21. Weinshenker BG, Bass BH, Ebers GC, et al. Remission of psoriatic lesions with muromonab-CD3 (orthoclone OKT3) treatment. J Am Acad Dermatol 1989;20:1132-3
22. Nicolas JF, Chamchick N, Thivolet J, et al. CD4 antibody treatment of severe psoriasis. Lancet 1991;338:321
23. Prinz J, Braun-Falco O, Meurer M, et al. Chimaeric CD4 monoclonal antibody in treatment of generalised pustular psoriasis. Lancet 1991;338:320-1
24. Gottlieb SL, Gilleaudeau P, Johnson R, et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med 1995;1:442-7
25. Kanamori H, Tanaka M, Kawaguchi H, et al. Resolution of psoriasis following allogeneic bone marrow transplantation for chronic myelogenous leukemia: case report and review of the literature. Am J Hematol 2002;71:41-4
26. Snowden JA, Heaton DC. Development of psoriasis after syngeneic bone marrow transplant from psoriatic donor: further evidence for adoptive autoimmunity. Br J Dermatol 1997; 137:130-2
27. Ellis CN, Krueger GG. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001;345:248-55
28. Lebwohl M, Tyring SK, Hamilton TK, et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003;349:2004-13
29. Chaudhari U, Romano P, Mulcahy LD, et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001;357:1842-7
30. Gordon KB, Langley RG, Leonardi C, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 2006;55:598-606
31. Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000;356:385-90
32. Lee E, Trepicchio WL, Oestreicher JL, et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 2004;199:125-30
33. Khader SA, Bell GK, Pearl JE, et al. IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol 2007;8:369-77
34. Egeter O, Mocikat R, Ghoreschi K, et al. Eradication of disseminated lymphomas with CpG-DNA activated T helper type 1 cells from nontransgenic mice. Cancer Res 2000;60:1515-20
35. Qin Z, Blankenstein T. CD4+ T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. Immunity 2000;12:677-86
36. Racke MK, Bonomo A, Scott DE, et al. Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease. J Exp Med 1994;180:1961-6
37. Bailey SL, Schreiner B, McMahon EJ, et al. CNS myeloid DCs presenting endogenous myelin peptides 'preferentially' polarize CD4+ T(H)-17 cells in relapsing EAE. Nat Immunol 2007;8:172-80
38. Falcone M, Bloom BR. A T helper cell 2 (Th2) immune response against non-self antigens modifies the cytokine profile of autoimmune T cells and protects against experimental allergic encephalomyelitis. J Exp Med 1997;185:901-7
39. Biedermann T, Mailhammer R, Mai A, et al. Reversal of established delayed type hypersensitivity reactions following therapy with IL-4 or antigen-specific Th2 cells. Eur J Immunol 2001;31:1582-91
40. Swain SL, Weinberg AD, English M, et al. IL-4 directs the development of Th2-like helper effectors. J Immunol 1990;145:3796-806
41. Rocken M, Urban J, Shevach EM. Antigen-specific activation, tolerization, and reactivation of the interleukin 4 pathway in vivo. J Exp Med 1994;179:1885-93
42. Rocken M, Saurat JH, Hauser C. A common precursor for CD4+ T cells producing IL-2 or IL-4. J Immunol 1992;148:1031-6
43. Horsfall AC, Butler DM, Marinova L, et al. Suppression of collagen-induced arthritis by continuous administration of IL-4. J Immunol 1997;159:5687-96
44. Cameron MJ, Arreaza GA, Zucker P, et al. IL-4 prevents insulitis and insulin-dependent diabetes mellitus in nonobese diabetic mice by potentiation of regulatory T helper-2 cell function. J Immunol 1997;159:4686-92
45. Seder RA, Paul WE, Davis MM, et al. The presence of interleukin 4 during in vitro priming determines the lymphokine-producing potential of CD4+ T cells from T cell receptor transgenic mice. J Exp Med 1992;176:1091-8
46. Kalinski P, Smits HH, Schuitemaker JH, et al. IL-4 is a mediator of IL-12p70 induction by human Th2 cells: reversal of polarized Th2 phenotype by dendritic cells. J Immunol 2000;165:1877-81
47. Hochrein H, O'Keeffe M, Luft T, et al. Interleukin (IL)-4 is a major regulatory cytokine governing bioactive IL-12 production by mouse and human dendritic cells. J Exp Med 2000;192:823-33
48. Biedermann T, Zimmermann S, Himmelrich H, et al. IL-4 instructs TH1 responses and resistance to Leishmania major in susceptible BALB/c mice. Nat Immunol 2001;2:1054-60
49. Isakson PC, Pure E, Vitetta ES, et al. T cell-derived B cell differentiation factor(s). Effect on the isotype switch of murine B cells. J Exp Med 1982;155:734-48
50. Snapper CM, Paul WE. Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. Science 1987;236:944-7
51. Mosmann TR, Bond MW, Coffman RL, et al. T-cell and mast cell lines respond to B-cell stimulatory factor 1. Proc Natl Acad Sci USA 1986;83:5654-8
52. Sanderson CJ, O'Garra A, Warren DJ, et al. Eosinophil differentiation factor also has B-cell growth factor activity: proposed name interleukin 4. Proc Natl Acad Sci USA 1986;83:437-40
53. Fernandez-Botran R, Sanders VM, Oliver KG, et al. Interleukin 4 mediates autocrine growth of helper T cells after antigenic stimulation. Proc Natl Acad Sci USA 1986;83:9689-93
54. Breit S, Steinhoff M, Blaser K, et al. A strict requirement of interleukin-4 for interleukin-4 induction in antigen-stimulated human memory T cells. Eur J Immunol 1996;26:1860-5
55. Ohara J, Paul WE. Receptors for B-cell stimulatory factor-1 expressed on cells of haematopoietic lineage. Nature 1987;325:537-40
56. Mosley B, Beckmann MP, March CJ, et al. The murine interleukin-4 receptor: molecular cloning and characterization of secreted and membrane bound forms. Cell 1989;59:335-48
57. Sato TA, Widmer MB, Finkelman FD, et al. Recombinant soluble murine IL-4 receptor can inhibit or enhance IgE responses in vivo. J Immunol 1993;150:2717-23
58. Keegan AD, Johnston JA, Tortolani PJ, et al. Similarities and differences in signal transduction by interleukin 4 and interleukin 13: analysis of Janus kinase activation. Proc Natl Acad Sci USA 1995;92:7681-5
59. Keegan AD, Nelms K, White M, et al. An IL-4 receptor region containing an insulin receptor motif is important for IL-4-mediated IRS-1 phosphorylation and cell growth. Cell 1994;76:811-20
60. Hou J, Schindler U, Henzel WJ, et al. An interleukin-4-induced transcription factor: IL-4 Stat. Science 1994;265:1701-6
61. Kaplan MH, Schindler U, Smiley ST, et al. Stat6 is required for mediating responses to IL-4 and for development of Th2 cells. Immunity 1996;4:313-9
62. Zheng W, Flavell RA. The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells. Cell 1997;89:587-96
63. Ho IC, Lo D, Glimcher LH. c-maf promotes T helper cell type 2 (Th2) and attenuates Th1 differentiation by both interleukin 4-dependent and -independent mechanisms. J Exp Med 1998;188:1859-66
64. Zhu J, Yamane H, Cote-Sierra J, et al. GATA-3 promotes Th2 responses through three different mechanisms: induction of Th2 cytokine production, selective growth of Th2 cells and inhibition of Th1 cell-specific factors. Cell Res 2006;16:3-10
65. Mantel PY, Kuipers H, Boyman O, et al. GATA3-driven Th2 responses inhibit TGF-beta1-induced FOXP3 expression and the formation of regulatory T cells. PLoS Biol 2007;5:2847-61
66. Yokota T, Otsuka T, Mosmann T, et al. Isolation and characterization of a human interleukin cDNA done, homologous to mouse B-cell stimulatory factor 1, that expresses B-cell- and T-cell-stimulating activities. Proc Natl Acad Sci USA 1986;83:5894-8
67. Tepper RI, Pattengale PK, Leder P. Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 1989;57:503-12
68. Atkins MB, Vachino G, Tilg HJ, et al. Phase I evaluation of thrice-daily intravenous bolus interleukin-4 in patients with refractory malignancy. J Clin Oncol 1992;10:1802-9
69. Kawakami Y, Rosenberg SA, Lotze MT. Interleukin 4 promotes the growth of tumor-infiltrating lymphocytes cytotoxic for human autologous melanoma. J Exp Med 1988;168:2183-91
70. Myers JN, Yasumura S, Suminami Y, et al. Growth stimulation of human head and neck squamous cell carcinoma cell lines by interleukin 4. Clin Cancer Res 1996;2:127-35
71. Whitehead RP, Unger JM, Goodwin JW, et al. Phase II trial of recombinant human interleukin-4 in patients with disseminated malignant melanoma: a Southwest Oncology Group study. J Immunother 1998;21:440-6
72. Whitehead RP, Lew D, Flanigan RC, et al. Phase II trial of recombinant human interleukin-4 in patients with advanced renal cell carcinoma: a southwest oncology group study. J Immunother 2002;25:352-8
73. Golumbek PT, Lazenby AJ, Levitsky HI, et al. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 1991;254:713-6
74. Chang GC, Lan HC, Juang SH, et al. A pilot clinical trial of vaccination with dendritic cells pulsed with autologous tumor cells derived from malignant pleural effusion in patients with late-stage lung carcinoma. Cancer 2005;103:763-71
75. Marsh DG, Neely JD, Breazeale DR, et al. Linkage analysis of IL4 and other chromosome 5q31.1 markers and total serum immunoglobulin E concentrations. Science 1994;264:1152-6
76. Rosa-Rosa L, Zimmermann N, Bernstein JA, et al. The R576 IL-4 receptor alpha allele correlates with asthma severity. J Allergy Clin Immunol 1999;104:1008-14
77. Loza MJ, Chang BL. Association between Q551R IL4R genetic variants and atopic asthma risk demonstrated by meta-analysis. J Allergy Clin Immunol 2007;120:578-85
78. Schipf A, Heilmann A, Boue L, et al. Th2 cells shape the differentiation of developing T cell responses during interactions with dendritic cells in vivo. Eur J Immunol 2003;33:1697-706
79. Borish LC, Nelson HS, Lanz MJ, et al. Interleukin-4 receptor in moderate atopic asthma. A Phase I/II randomized, placebo-controlled trial. Am J Respir Crit Care Med 1999;160:1816-23
80. Borish LC, Nelson HS, Corren J, et al. Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J Allergy Clin Immunol 2001;107:963-70
81. Wenzel S, Wilbraham D, Fuller R, et al. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet 2007;370:1422-31
82. Ghoreschi K, Rocken M. Molecular and cellular basis for designing gene vaccines against inflammatory autoimmune disease. Trends Mol Med 2003;9:331-8
83. Harrington LE, Hatton RD, Mangan PR, et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005;6:1123-32
84. Sornasse T, Larenas PV, Davis KA, et al. Differentiation and stability of T helper 1 and 2 cells derived from naive human neonatal CD4+ T cells, analyzed at the single-cell level. J Exp Med 1996;184:473-83
85. Austin LM, Ozawa M, Kikuchi T, et al. The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J Invest Dermatol 1999;113:752-9
86. Leach MW, Rybak ME, Rosenblum IY. Safety evaluation of recombinant human interleukin-4. II. Clinical studies. Clin Immunol Immunopathol 1997;83:12-4
87. Asadullah K, Sabat R, Friedrich M, et al. Interleukin-10: an important immunoregulatory cytokine with major impact on psoriasis. Curr Drug Targets Inflamm Allergy 2004;3:185-92
88. Asadullah K, Sterry W, Stephanek K, et al. IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach. J Clin Invest 1998;101:783-94
89. Friedrich M, Döcke WD, Klein A, et al. Immunomodulation by interleukin-10 therapy decreases the incidence of relapse and prolongs the relapse-free interval in Psoriasis. J Invest Dermatol 2002;118:672-7
90. Kimball AB, Kawamura T, Tejura K, et al. Clinical and immunologic assessment of patients with psoriasis in a randomized, double-blind, placebo-controlled trial using recombinant human interleukin 10. Arch Dermatol 2002;138:1341-6
91. Ciurea SO, Hoffman R. Cytokines for the treatment of thrombocytopenia. Semin Hematol 2007;44:166-82
92. Bozza M, Bliss JL, Dorner AJ, et al. Interleukin-11 modulates Th1/Th2 cytokine production from activated CD4+ T cells. J Interferon Cytokine Res 2001;21:21-30
93. Curti A, Ratta M, Corinti S, et al. Interleukin-11 induces Th2 polarization of human CD4(+) T cells. Blood 2001;97:2758-63
94. Trepicchio WL, Ozawa M, Walters IB, et al. Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions. J Clin Invest 1999;104:1527-37
95. Trembleau S, Penna G, Gregori S, et al. Deviation of pancreas-infiltrating cells to Th2 by interleukin-12 antagonist administration inhibits autoimmune diabetes. Eur J Immunol 1997;27:2330-9
96. Langrish CL, McKenzie BS, Wilson NJ, et al. IL-12 and IL-23: master regulators of innate and adaptive immunity. Immunol Rev 2004;202:96-105
97. Williamson E, Garside P, Bradley JA, et al. Neutralizing IL-12 during induction of murine acute graft-versus-host disease polarizes the cytokine profile toward a Th2-type alloimmune response and confers long term protection from disease. J Immunol 1997;159:1208-15
98. Chen Y, Langrish CL, McKenzie B, et al. Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis. J Clin Invest 2006;116:1317-26
99. Kauffman CL, Aria N, Toichi E, et al. A Phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J Invest Dermatol 2004;123:1037-44
100. Toichi E, Torres G, McCormick TS, et al. An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis. J Immunol 2006;177:4917-26
101. Krueger GG, Langley RG, Leonardi C, et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 2007;356:580-92
102. Ghoreschi K, Mrowietz U, Rocken M. A molecule solves psoriasis? Systemic therapies for psoriasis inducing interleukin 4 and Th2 responses. J Mol Med 2003;81:471-80